{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T12:49:42Z","timestamp":1794660582501,"version":"4.9.1"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":273,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2021]]},"DOI":"10.6061\/clinics\/2021\/e3015","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T15:24:44Z","timestamp":1632929084000},"page":"e3015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Immunogenicity to biological drugs in psoriasis and psoriatic arthritis"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1032-9347","authenticated-orcid":false,"given":"Fernando","family":"Valenzuela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2924-1073","authenticated-orcid":false,"given":"Rodrigo","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.6061\/clinics\/2021\/e3015_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01951","article-title":"The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment with Monoclonal Antibodies","volume":"11","author":"Vaisman-Mentesh","year":"2020","journal-title":"Front Immunol"},{"issue":"5","key":"10.6061\/clinics\/2021\/e3015_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.6061\/clinics\/2021\/e3015_bib3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40257-015-0131-y","article-title":"Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate","volume":"16","author":"Farhangian","year":"2015","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.6061\/clinics\/2021\/e3015_bib4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","article-title":"The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases","volume":"53","author":"Jani","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.6061\/clinics\/2021\/e3015_bib5","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.4067\/S0034-98872003001200013","article-title":"Nuevas armas inmunol\u00f3gicas para la medicina del siglo XXI: terapia biol\u00f3gica basada en el uso de anticuerpos monoclonales de \u00faltima generaci\u00f3n","volume":"131","author":"Aguill\u00f3n","year":"2003","journal-title":"Rev Med Chil"},{"issue":"1","key":"10.6061\/clinics\/2021\/e3015_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/antib8010021","article-title":"Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies","volume":"8","author":"Doevendans","year":"2019","journal-title":"Antibodies (Basel)"},{"key":"10.6061\/clinics\/2021\/e3015_bib7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000478077","article-title":"The Immunogenicity of Biologic Therapies","volume":"53","author":"Garc\u00eas","year":"2018","journal-title":"Curr Probl Dermatol"},{"issue":"6","key":"10.6061\/clinics\/2021\/e3015_bib8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/1744666X.2018.1468753","article-title":"Immunogenicity of biologic therapies: causes and consequences","volume":"14","author":"Boehncke","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"10.6061\/clinics\/2021\/e3015_bib9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/FTD.0000000000000404","article-title":"Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context","volume":"39","author":"Bloem","year":"2017","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.6061\/clinics\/2021\/e3015_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/17512433.2020.1772053","article-title":"Immunogenicity-unwanted immune responses to biological drugs - can we predict them?","volume":"14","author":"Matucci","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.6061\/clinics\/2021\/e3015_bib11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fimmu.2016.00021","article-title":"Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes","volume":"7","author":"Krishna","year":"2016","journal-title":"Front Immunol"},{"issue":"1","key":"10.6061\/clinics\/2021\/e3015_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/jid.2014.295","article-title":"Immunogenicity of biotherapy used in psoriasis: the science behind the scenes","volume":"135","author":"Jullien","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.6061\/clinics\/2021\/e3015_bib13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/FTD.0000000000000404","article-title":"Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context","volume":"39","author":"Bloem","year":"2017","journal-title":"Ther Drug Monit"},{"issue":"9","key":"10.6061\/clinics\/2021\/e3015_bib14","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.6061\/clinics\/2021\/e3015_bib15","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/jjco\/hyu049","article-title":"Severe infusion reactions to cetuximab occur within 1 h in patients with metastatic colorectal cancer: results of a nationwide, multicenter, prospective registry study of 2126 patients in Japan","volume":"44","author":"Yamaguchi","year":"2014","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"10.6061\/clinics\/2021\/e3015_bib16","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.clim.2009.05.007","article-title":"Immunogenicity of rituximab in patients with severe pemphigus","volume":"132","author":"Schmidt","year":"2009","journal-title":"Clin Immunol"},{"key":"10.6061\/clinics\/2021\/e3015_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/1756283X17750355","article-title":"Immunogenicity of biologics in inflammatory bowel disease","volume":"11","author":"Vermeire","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"issue":"1","key":"10.6061\/clinics\/2021\/e3015_bib18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jaip.2018.06.011","article-title":"The percentage of patients achieving complete remission of urticaria increases with repeated courses of treatment","volume":"7","author":"Matucci","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"10.6061\/clinics\/2021\/e3015_bib19","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/annrheumdis-2012-201544","article-title":"Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner","volume":"71","author":"Krieckaert","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.6061\/clinics\/2021\/e3015_bib20","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1136\/gutjnl-2019-319758","article-title":"Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial","volume":"69","author":"Roblin","year":"2020","journal-title":"Gut"},{"issue":"6","key":"10.6061\/clinics\/2021\/e3015_bib21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ad.2013.02.005","article-title":"Immunogenicity in biologic therapy: Implications for dermatology","volume":"104","author":"Carrascosa","year":"2013","journal-title":"Actas Dermosifiliogr"},{"issue":"3","key":"10.6061\/clinics\/2021\/e3015_bib22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijwd.2016.05.001","article-title":"A dermatologist guide to immunogenicity","volume":"2","author":"Blattner","year":"2016","journal-title":"Int J Womens Dermatol"},{"issue":"2","key":"10.6061\/clinics\/2021\/e3015_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41584-020-00540-8","article-title":"Immunogenicity of biologic agents in rheumatology","volume":"17","author":"Strand","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.6061\/clinics\/2021\/e3015_bib24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.iac.2017.01.012","article-title":"Adverse Reactions to Biologic Therapy","volume":"37","author":"Patel","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"issue":"3","key":"10.6061\/clinics\/2021\/e3015_bib25","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/1346-8138.14139","article-title":"Pathogenesis of psoriasis and development of treatment","volume":"45","author":"Ogawa","year":"2018","journal-title":"J Dermatol"},{"issue":"3","key":"10.6061\/clinics\/2021\/e3015_bib26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.6061\/clinics\/2021\/e3015_bib27","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cyto.2018.08.025","article-title":"Differential efficacy of biologic treatments targeting the TNF-\u03b1\/IL-23\/IL-17 axis in psoriasis and psoriatic arthritis","volume":"111","author":"Furue","year":"2018","journal-title":"Cytokine"},{"issue":"9997","key":"10.6061\/clinics\/2021\/e3015_bib28","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"10.6061\/clinics\/2021\/e3015_bib29","first-page":"113","article-title":"Actualizaci\u00f3n en terapia biol\u00f3gica para psoriasis y artritis psori\u00e1tica (parte I): mol\u00e9culas peque\u00e3as, inhibidores de JAK y agentes biol\u00f3gicos (inhibidores IL-17)","volume":"2","author":"Flores","year":"2020","journal-title":"Lat Am J Clin Sci Med Technol"},{"issue":"3","key":"10.6061\/clinics\/2021\/e3015_bib30","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12916","article-title":"Biologics for psoriasis: What is new?","volume":"32","author":"\u00d6zyurt","year":"2019","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.6061\/clinics\/2021\/e3015_bib31","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/jdv.16980","article-title":"Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach","volume":"35","author":"Tsakok","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.6061\/clinics\/2021\/e3015_bib32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.gendis.2020.02.004","article-title":"Therapeutic potential of TNF\u03b1 inhibitors in chronic inflammatory disorders: Past and future","volume":"8","author":"Zhang","year":"2020","journal-title":"Genes Dis"},{"issue":"12","key":"10.6061\/clinics\/2021\/e3015_bib33","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1517\/14712598.2013.848194","article-title":"Immunogenicity of anti-TNF\u03b1 therapy in psoriasis: a clinical issue?","volume":"13","author":"De Simone","year":"2013","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"10.6061\/clinics\/2021\/e3015_bib34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/bjd.12654","article-title":"Antidrug antibodies in psoriasis: a systematic review","volume":"170","author":"Hsu","year":"2014","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.6061\/clinics\/2021\/e3015_bib35","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.berh.2011.10.004","article-title":"Anti-TNF therapy","volume":"25","author":"Thalayasingam","year":"2011","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"10.6061\/clinics\/2021\/e3015_bib36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","article-title":"Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study","volume":"77","author":"Mariette","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.6061\/clinics\/2021\/e3015_bib37","first-page":"59","article-title":"Individualizaci\u00f3n de la terapia con infliximab: monitorizaci\u00f3n farmacocin\u00e9tica","volume":"39","author":"Santacana-Juncosa","year":"2015","journal-title":"Farm Hosp"},{"issue":"3","key":"10.6061\/clinics\/2021\/e3015_bib38","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs"},{"issue":"6","key":"10.6061\/clinics\/2021\/e3015_bib39","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.autrev.2017.04.002","article-title":"The impact of immunogenicity of TNF\u03b1 inhibitors in autoimmune inflammatory disease. A systematic review and meta-analysis","volume":"16","author":"Pecoraro","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.6061\/clinics\/2021\/e3015_bib40","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.semarthrit.2018.10.006","article-title":"Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis","volume":"48","author":"Quistrebert","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.6061\/clinics\/2021\/e3015_bib41","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/art.22552","article-title":"A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response","volume":"57","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.6061\/clinics\/2021\/e3015_bib42","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1080\/09546634.2017.1296927","article-title":"Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study","volume":"28","author":"Ara-Mart\u00edn","year":"2017","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.6061\/clinics\/2021\/e3015_bib43","doi-asserted-by":"crossref","first-page":"31.e1","DOI":"10.1016\/j.jaad.2006.07.017","article-title":"A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis","volume":"56","author":"Menter","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.6061\/clinics\/2021\/e3015_bib44","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0213-9251(08)75133-5","article-title":"Tratamiento de la psoriasis en placas moderada y grave con etanercept","volume":"23","author":"Manel Casanova","year":"2008","journal-title":"Piel"},{"issue":"4","key":"10.6061\/clinics\/2021\/e3015_bib45","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.6061\/clinics\/2021\/e3015_bib46","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/ard.2006.058339","article-title":"Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial","volume":"66","author":"Kavanaugh","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.6061\/clinics\/2021\/e3015_bib47","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.6061\/clinics\/2021\/e3015_bib48","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1136\/annrheumdis-2014-205554","article-title":"Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up","volume":"73","author":"Vogelzang","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.6061\/clinics\/2021\/e3015_bib49","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.143.6.719","article-title":"Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis","volume":"143","author":"Tyring","year":"2007","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.6061\/clinics\/2021\/e3015_bib50","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/rheumatology\/key309","article-title":"Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis","volume":"58","author":"Leu","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.6061\/clinics\/2021\/e3015_bib51","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40259-020-00416-z","article-title":"Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis","volume":"34","author":"Lee","year":"2020","journal-title":"BioDrugs"},{"issue":"4","key":"10.6061\/clinics\/2021\/e3015_bib52","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/bjd.19314","article-title":"Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies","volume":"184","author":"Blauvelt","year":"2021","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.6061\/clinics\/2021\/e3015_bib53","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13075-019-2009-5","article-title":"Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study","volume":"21","author":"Gehin","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.6061\/clinics\/2021\/e3015_bib54","doi-asserted-by":"crossref","first-page":"306","DOI":"10.55563\/clinexprheumatol\/nlr4r8","article-title":"The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation","volume":"38","author":"Berkhout","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.6061\/clinics\/2021\/e3015_bib55","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaad.2018.04.013","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)","volume":"79","author":"Lebwohl","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.6061\/clinics\/2021\/e3015_bib56","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/bjd.19393","article-title":"Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2)","volume":"184","author":"Gordon","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.6061\/clinics\/2021\/e3015_bib57","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaut.2015.07.008","article-title":"The immunogenetics of Psoriasis: A comprehensive review","volume":"64","author":"Harden","year":"2015","journal-title":"J Autoimmun"},{"issue":"7","key":"10.6061\/clinics\/2021\/e3015_bib58","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/exd.13676","article-title":"Inhibition of interleukin-12 and\/or interleukin-23 for the treatment of psoriasis: What is the evidence for an effect on malignancy?","volume":"27","author":"Ergen","year":"2018","journal-title":"Exp Dermatol"},{"key":"10.6061\/clinics\/2021\/e3015_bib59","first-page":"208","article-title":"Actualizaci\u00f3n en terapia biol\u00f3gica para psoriasis y artritis psori\u00e1tica (parte II): agentes biol\u00f3gicos (inhibidores IL-23)","author":"Flores","year":"2020","journal-title":"Lat Am J Clin Sci Med Technol"},{"issue":"1","key":"10.6061\/clinics\/2021\/e3015_bib60","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ecco-jcc\/jjz110","article-title":"IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn\u2019s Disease","volume":"14","author":"Hanauer","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"9625","key":"10.6061\/clinics\/2021\/e3015_bib61","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.6061\/clinics\/2021\/e3015_bib62","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1749-6632.2011.05963.x","article-title":"Development of the IL-12\/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives","volume":"1222","author":"Yeilding","year":"2011","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"10.6061\/clinics\/2021\/e3015_bib63","doi-asserted-by":"crossref","first-page":"247","DOI":"10.5114\/ada.2016.61599","article-title":"Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases","volume":"33","author":"Wasilewska","year":"2016","journal-title":"Postepy Dermatol Alergol"},{"issue":"3","key":"10.6061\/clinics\/2021\/e3015_bib64","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1080\/19420862.2015.1136761","article-title":"Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity","volume":"8","author":"Karle","year":"2016","journal-title":"MAbs"},{"issue":"9","key":"10.6061\/clinics\/2021\/e3015_bib65","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1111\/jdv.15637","article-title":"Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years","volume":"33","author":"Reich","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.6061\/clinics\/2021\/e3015_bib66","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/14712598.2020.1729736","article-title":"Ixekizumab for the treatment of psoriasis: up-to-date","volume":"20","author":"Craig","year":"2020","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"10.6061\/clinics\/2021\/e3015_bib67","doi-asserted-by":"crossref","first-page":"AB258","DOI":"10.1016\/j.jaad.2016.02.999","article-title":"Ixekizumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis","volume":"74","author":"Blauvelt","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.6061\/clinics\/2021\/e3015_bib68","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.jid.2018.04.019","article-title":"Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis","volume":"138","author":"Reich","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.6061\/clinics\/2021\/e3015_bib69","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/09546634.2018.1473552","article-title":"Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis","volume":"30","author":"Thomas","year":"2019","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"10.6061\/clinics\/2021\/e3015_bib70","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jaad.2019.05.094","article-title":"Immunogenicity and skin clearance recapture in clinical studies of brodalumab","volume":"82","author":"Bagel","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.6061\/clinics\/2021\/e3015_bib71","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1080\/21645515.2017.1356498","article-title":"Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis","volume":"13","author":"Jeon","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"10.6061\/clinics\/2021\/e3015_bib72","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40261-017-0550-z","article-title":"Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis","volume":"37","author":"Chen","year":"2017","journal-title":"Clin Drug Investig"},{"issue":"7551","key":"10.6061\/clinics\/2021\/e3015_bib73","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature14175","article-title":"Clinical improvement in psoriasis with specific targeting of interleukin-23","volume":"521","author":"Kopp","year":"2015","journal-title":"Nature"},{"issue":"3","key":"10.6061\/clinics\/2021\/e3015_bib74","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.6061\/clinics\/2021\/e3015_bib75","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.6061\/clinics\/2021\/e3015_bib76","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.jid.2019.02.018","article-title":"Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis","volume":"139","author":"Zhu","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.6061\/clinics\/2021\/e3015_bib77","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40257-019-00435-9","article-title":"Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis","volume":"20","author":"Frampton","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.6061\/clinics\/2021\/e3015_bib78","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/bjd.17918","article-title":"Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab","volume":"182","author":"Kimball","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.6061\/clinics\/2021\/e3015_bib79","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40262-019-00842-5","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients","volume":"59","author":"Pang","year":"2020","journal-title":"Clin Pharmacokinet"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S180759322200206X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S180759322200206X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:56:12Z","timestamp":1761720972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S180759322200206X"},"secondary":[{"URL":"https:\/\/www.scielo.br\/j\/clin\/a\/78Sc3XQhnJPLtynB4J9FWSq\/?lang=en","label":"SCIELO"},{"URL":"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8449932\/","label":"PMC"},{"URL":"https:\/\/www.clinicsjournal.com\/article\/immunogenicity-to-biological-drugs-in-psoriasis-and-psoriatic-arthritis\/","label":"CLINICS"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":79,"alternative-id":["S180759322200206X"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2021\/e3015","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity to biological drugs in psoriasis and psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2021\/e3015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}],"article-number":"e3015"}}